Browse Category

Company Updates News 25 September 2025 - 6 November 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported third‑quarter 2025 results this morning (Nov. 6), highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte (TIL) therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged
Datadog (DDOG) Jumps After Q3 2025 Beat: $886M Revenue, $0.55 EPS; Full‑Year Outlook Raised

Datadog (DDOG) Jumps After Q3 2025 Beat: $886M Revenue, $0.55 EPS; Full‑Year Outlook Raised

Cloud observability and security provider Datadog (NASDAQ: DDOG) posted a stronger‑than‑expected third quarter and lifted its full‑year guidance, citing continued momentum with large customers and rapid product innovation in AI observability and security. The company reported revenue of $886 million
1 3 4 5
Go toTop